Bupropion for fatigue and as a tumor necrosis factor-α lowering agent in primary biliary cirrhosis

Medical Hypotheses

Volumn 64, Issue 1, 2005, Pages 118-119

  Altschuler, Eric Lewin ^a,b   Kast, Richard E ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; TUMOR NECROSIS FACTOR ALPHA;

DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; HUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; SHORT SURVEY;

EID: 7944232726     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2003.11.044     Document Type: Article

References (13)

1. Talwalker J.A., Lindor K.D. Primary biliary cirrhosis. Lancet. 362:2003;53-61
2. Cauch-Dudek K., Abbey S., Stewart D.E., Heathcote E.J. Fatigue in primary biliary cirrhosis. Gut. 43:1998;705-710
3. Goldblatt J., Taylor P.J., Lipman T., Prince M.I., Baragiotta A., Bassendine M.F., et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology. 122:2002;1235-1241
4. Kast R.E., Altschuler E.L. Remission of Crohn's disease on bupropion. Gastroenterology. 121:2001;1260-1261
5. Kast R.E., Altschuler E.L. Tumor necrosis factor-α in hepatitis B: potential role for bupropion. J. Hepatol. 39:2003;131-133
6. Altschuler E.L., Kast R.E. Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-α? Psychosom. Med. 65:2003
7. Neuman M.G., Angulo P., Malkiewicz I.M., Ben-Ari Z., Schmilovitz-Weiss H., Lindor K.D. Ursodeoxycholic acid therapy inhibits tumor necrosis factor-α signaling for apoptosis by reducing caspase activity in patients with primary biliary cirrhosis (late-breaking abstract digestive diseases week (DDW) 2003). J. Hepatol. 38:2003;277
8. Gobbi G., Slater S., Boucher N., Debonnel G., Blier P. Neurochemical and psychotrophic effects of bupropion in healthy male subjects. J. Clin. Psychopharmacol. 23:2003;233-239
9. Nieuwstraten C.E., Dolovich L.R. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann. Pharmacother. 35:2001;1608-1613
10. Kast R.E. Crohn's disease remission with phenelzine treatment. Gastroenterology. 115:1998;1034-1035
11. Talmadge J., Scott R., Castelli P., Newman-Tarr T., Lee J. Molecular pharmacology of the beta-adrenergic receptor on THP-1 cells. Int. J. Immunopharmacol. 15:1993;219-228
12. Guirao X., Kumar A., Katz J., Smith M., Lin E., Keogh C., et al. Catecholamines increase monocyte TNF receptors and inhibit TNF through β-2 adrenoreceptor activation. Am. J. Physiol. 273:1997;E1203-1208
13. Modell J.G., Boyce S., Taylor E., Katholi C. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom. Med. 64:2002;835-840